NewsHow does causalStudio™ address the key regulatory requirements for data integrity, traceability, and analysis?Read more →Read more →
How does causalStudio™ address the key regulatory requirements for data integrity, traceability, and analysis?Read more →
An Overview of MASH: Advancements in Diagnosis, Treatment, and the Role of Real-World DataRead more →
Addressing the Burden of Hidradenitis Suppurativa: The Often-Hidden Impact on Quality of LifeRead more →
Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology StudiesRead more →
New Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLDRead more →
Target RWE Highlights GLP-1 Receptor Agonists in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease at The Liver Meeting 2024Read more →
ACG 2024: Target RWE Presents Key MASH and EGIDs Data from Leading Liver Disease & Gastroenterology Real-World RegistriesRead more →
Transforming Healthcare Through Data: Ewa J. Kleczyk on Precision Medicine, Diversity, and AI ChallengesRead more →
Target RWE Announces the Launch of engage™ - An Innovative, Digital Patient-Centric Engagement PlatformRead more →
Real World TARGET-NASH Analysis Shows High Concordance Between New MASLD Definitions and Prior TARGET-NASH Pragmatic DefinitionsRead more →
Overcoming Scalability Challenges in Real-World Data Processing for Transformative Patient CareRead more →
TARGET-NASH Offers Unprecedented Glimpse into Growing Public Health Concerns with Few Treatment OptionsRead more →
Leveraging Real-World Evidence with Analytics: 3 Essential Components to Capture a 360-Degree View of Your Patient PopulationRead more →
Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASHRead more →
Longest Running Real World Dermatology Registry, TARGET-DERM, Offers Deep Insight into Complex DiseasesRead more →
New Approaches for Developing Real-World Evidence Presented by Target RWE at the 2022 International Conference on Pharmacoepidemiology (ICPE)Read more →
Durham-Based Target RWE Grows Data Abstraction, Curation Capabilities with Latest AcquisitionRead more →
Real-World Data Finds High Prevalence of Pruritus (Itching) and Fatigue, Low Levels of Treatment in Primary Biliary Cholangitis PopulationRead more →
Large Real-World Study Uncovers Higher Prevalence of Non-Alcoholic Fatty Liver Disease Markers, Liver Biopsy, and Cirrhosis in ChildrenRead more →
TARGET-IBD Study Reveals Nearly a Third of Patients with Inflammatory Bowel Disease Did Not Undergo Objective Assessment Prior to Biologic Dose Change, DiscontinuationRead more →
Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and SciencesRead more →
Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger PatientsRead more →
TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart DiseaseRead more →
Target RWE COVID-19 Data: Real-World Evidence Analysis Shows 3.6% of COVID-19 Hospitalized Patients Discharged Alive Required ReadmissionRead more →
TARGET-NASH Real-World Study Reveals Two Thirds Of Patients With NAFLD Had No Record Of Liver BiopsyRead more →
Target RWE Acquires NoviSci Inc., Adding Significant Analytical Capabilities to Leading Real-World Evidence PlatformRead more →
TARGET-IBD Research Receives Presidential Poster Award And Outstanding Presenter Award At 2019 American College Of Gastroenterology Annual Scientific MeetingRead more →
